| Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging LS Steelman, WH Chappell, SL Abrams, CR Kempf, J Long, P Laidler, ... Aging (Albany NY) 3 (3), 192, 2011 | 617 | 2011 |
| Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health WH Chappell, LS Steelman, JM Long, RC Kempf, SL Abrams, RA Franklin, ... Oncotarget 2 (3), 135, 2011 | 538 | 2011 |
| GSK-3 as potential target for therapeutic intervention in cancer JA McCubrey, LS Steelman, FE Bertrand, NM Davis, M Sokolosky, ... Oncotarget 5 (10), 2881, 2014 | 379 | 2014 |
| Vitamin D3: a helpful immuno‐modulator M Di Rosa, M Malaguarnera, F Nicoletti, L Malaguarnera Immunology 134 (2), 123-139, 2011 | 377 | 2011 |
| ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis Y Al-Abed, D Dabideen, B Aljabari, A Valster, D Messmer, M Ochani, ... Journal of Biological Chemistry 280 (44), 36541-36544, 2005 | 326 | 2005 |
| Molecular mechanisms involved in NAFLD progression M Malaguarnera, M Di Rosa, F Nicoletti, L Malaguarnera Journal of molecular medicine 87 (7), 679-695, 2009 | 300 | 2009 |
| Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance JA McCubrey, LS Steelman, WH Chappell, SL Abrams, RA Franklin, ... Oncotarget 3 (10), 1068, 2012 | 293 | 2012 |
| Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response JA McCubrey, LS Steelman, WH Chappell, SL Abrams, G Montalto, ... Oncotarget 3 (9), 954, 2012 | 283 | 2012 |
| The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients AM Martelli, C Evangelisti, F Chiarini, JA McCubrey Oncotarget 1 (2), 89, 2010 | 261 | 2010 |
| Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy LS Steelman, RA Franklin, SL Abrams, W Chappell, CR Kempf, J Bäsecke, ... Leukemia 25 (7), 1080-1094, 2011 | 245 | 2011 |
| Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention NM Davis, M Sokolosky, K Stadelman, SL Abrams, M Libra, S Candido, ... Oncotarget 5 (13), 4603, 2014 | 238 | 2014 |
| Biphasic effect of interferon‐γ in murine collagen‐induced arthritis MC Boissier, G Chiocchia, N Bessis, J Hajnal, G Garotta, F Nicoletti, ... European journal of immunology 25 (5), 1184-1190, 1995 | 232 | 1995 |
| Targeting the leukemic stem cell: the Holy Grail of leukemia therapy N Misaghian, G Ligresti, LS Steelman, FE Bertrand, J Bäsecke, M Libra, ... Leukemia 23 (1), 25-42, 2009 | 216 | 2009 |
| Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome PL Meroni, E Raschi, M Camera, C Testoni, F Nicoletti, A Tincani, ... Journal of Autoimmunity 15 (2), 237-240, 2000 | 202 | 2000 |
| Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention JA McCubrey, LS Steelman, FE Bertrand, NM Davis, SL Abrams, ... Leukemia 28 (1), 15-33, 2014 | 187 | 2014 |
| Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway AM Martelli, C Evangelisti, W Chappell, SL Abrams, J Bäsecke, F Stivala, ... Leukemia 25 (7), 1064-1079, 2011 | 187 | 2011 |
| Serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed type I diabetes mellitus patients and subjects at risk of … F Nicoletti, I Conget, M Di Mauro, R Di Marco, MC Mazzarino, K Bendtzen, ... Diabetologia 45 (8), 1107-1110, 2002 | 174 | 2002 |
| PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches G Ligresti, L Militello, LS Steelman, A Cavallaro, F Basile, F Nicoletti, ... Cell cycle 8 (9), 1352-1358, 2009 | 173 | 2009 |
| Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways JA McCubrey, LS Steelman, CR Kempf, WH Chappell, SL Abrams, ... Journal of cellular physiology 226 (11), 2762-2781, 2011 | 167 | 2011 |
| Akt as a therapeutic target in cancer LS Steelman, KM Stadelman, WH Chappell, S Horn, J Bäsecke, ... Expert opinion on therapeutic targets 12 (9), 1139-1165, 2008 | 145 | 2008 |
